Hung Kam Cheung

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

Thomas U. Marron, Maria Isabel Fiel, Pauline Hamon et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 207 citations · Full text

Surgical Oncology, Hepatology, Resectable Hepatocellular Carcinoma +10

Successful shape-Based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)

Juswinder Singh, Claudio Chuaqui, P. Ann Boriack‐Sjodin et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 166 citations · Full text

Virtual Screening, Tgfβ Receptor Kinase, Engineering +8

A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth <i>In vivo</i> and Prevents Tumor Recurrence after Surgical Resection

Eiji Suzuki, Samuel Kim, Hung Kam Cheung et al. · Cancer Research · 2007 · 113 citations

SM16, an Orally Active TGF-β Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model

Kai Fu, Michael J. Corbley, Lihong Sun et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2008 · 84 citations · Full text

Systemic Blockade of Transforming Growth Factor-β Signaling Augments the Efficacy of Immunogene Therapy

Samuel Kim, George Buchlis, Zvi G. Fridlender et al. · Cancer Research · 2008 · 83 citations · Full text